Sg Americas Securities, LLC Cel Sci Corp Transaction History

Sg Americas Securities, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$7.1 - $12.82 $104,256 - $188,248	-14,684 Closed	0 $0
Q3 2021 Nov 01, 2021	BUY	$7.64 - $12.49 $112,185 - $183,403	14,684 New	14,684 $161,000
Q2 2021 Aug 12, 2021	SELL	$8.68 - $27.49 $60,621 - $191,990	-6,984 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$12.0 - $27.64 $807,456 - $1.86 Million	-67,288 Reduced 90.6%	6,984 $106,000
Q4 2020 Feb 04, 2021	SELL	$11.05 - $16.62 $1.33 Million - $2.01 Million	-120,697 Reduced 61.91%	74,272 $866,000
Q3 2020 Nov 09, 2020	BUY	$11.69 - $14.54 $1.59 Million - $1.97 Million	135,799 Added 229.51%	194,969 $2.49 Million
Q2 2020 Jul 20, 2020	BUY	$9.75 - $17.6 $466,908 - $842,828	47,888 Added 424.46%	59,170 $883,000
Q1 2020 Apr 30, 2020	SELL	$7.54 - $17.05 $1.16 Million - $2.62 Million	-153,463 Reduced 93.15%	11,282 $130,000
Q4 2019 Jan 28, 2020	BUY	$6.71 - $9.55 $1.11 Million - $1.57 Million	164,745 New	164,745 $1.51 Million

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.